iTeos Therapeutics

ITOS49

$8.23arrow_drop_down2.65%-$0.22

ITOS49

$8.23

arrow_drop_down2.65%-$0.22

Performance History

Key Stats
Open	$8.74
Prev. Close	$8.83
EPS	-2.96
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	8.32	8.83
52 Week Range	8.20	18.75

Ratios







EPS	-2.96

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About iTeos Therapeutics (ITOS)

iTeos Therapeutics, Inc. (ITOS) is a biotechnology company that focuses on discovering and developing innovative cancer immunotherapies. The company is dedicated to transforming the lives of cancer patients by harnessing the power of the immune system. iTeos Therapeutics, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.

The stock price history of iTeos Therapeutics, Inc. (ITOS) shows a promising trend. Over the past year, the stock has experienced significant growth, with the share price more than doubling. This positive momentum can be attributed to the company's strong pipeline of promising cancer immunotherapies.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Michel Detheux Ph.D.
Headquarters: Watertown
Employees: 125
Exchange: NASDAQ

Keep an eye on iTeos Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is iTeos Therapeutics's (ITOS) price per share?

The current price per share for iTeos Therapeutics (ITOS) is $8.23. The stock has seen a price change of -$0.23 recently, indicating a -2.66% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for iTeos Therapeutics (ITOS)?

For iTeos Therapeutics (ITOS), the 52-week high is $18.75, which is 127.83% from the current price. The 52-week low is $8.01, the current price is 2.81% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is iTeos Therapeutics (ITOS) a growth stock?

iTeos Therapeutics (ITOS) has shown an average price growth of -4.94% over the past three years. It has received a score of 12 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying iTeos Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is iTeos Therapeutics (ITOS) stock price performance year to date (YTD)?

As of the latest data, iTeos Therapeutics (ITOS) has a year-to-date price change of -28.99%. Over the past month, the stock has experienced a price change of -12.63%. Over the last three months, the change has been -46.59%. Over the past six months, the figure is -54.18%.

help

Is iTeos Therapeutics (ITOS) a profitable company?

iTeos Therapeutics (ITOS) has a net income of -$112.64M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 92.87% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -417.41% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $12.6M, although specific revenue growth data is currently not available. The gross profit is $11.7M. Operating income is noted at -$151.1M. Furthermore, the EBITDA is -$139.26M.

help

What is the market capitalization of iTeos Therapeutics (ITOS)?

iTeos Therapeutics (ITOS) has a market capitalization of $300.57M. The average daily trading volume is 8.24, indicating the stock's liquidity and investor engagement.

News

iTeos annonce ses résultats financiers pour le troisième trimestre 2024 et fait le point sur ses activités

iTeos verkündet Finanzergebnisse für das dritte Quartal 2024 und gibt aktuelle Geschäftsinformationen bekannt

iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates

ITEOS THERAPEUTICS

INUPADÉNANT

A2A RECEPTOR ANTAGONIST

NON-SMALL CELL LUNG CANCER

Oct 25, 2024

iTeos Therapeutics présentera les données précliniques et translationnelles portant sur l’inupadénant, ainsi que les résultats de l’essai clinique de Phase 2 A2A-005 portant sur le traitement en deuxième ligne du CPNPC lors du Congrès d’immuno-oncologie de l’ESMO

ITEOS THERAPEUTICS

INUPADENANT

NSCLC

ESMO IMMUNO-ONCOLOGY CONGRESS

Oct 25, 2024

iTeos Therapeutics präsentiert auf dem Immunonkologie-Kongress der ESMO präklinische und translationale Daten sowie Daten aus der klinischen Phase-II-Studie A2A-005 zu Inupadenant bei NSCLC in der Zweitlinie

ITEOS THERAPEUTICS

BELRESTOTUG

DOSTARLIMAB

NON-SMALL CELL LUNG CANCER

PD-L1

Sep 15, 2024

iTeos gibt klinisch bedeutsame objektive Ansprechrate bekannt – Beobachtung bei jeder Dosis in der Zwischenanalyse des Nachbeobachtungszeitraums der GALAXIES Lung-201-Studie zu Belrestotug + Dostarlimab bei Patienten mit nicht-kleinzelligem Lungenkrebs mit hoher PD-L1-Expression in der Erstlinienbehandlung

Performance History

Score Breakdown

Welcome to Stocklytics

Analyst Forecast

Analyst Ratings

About iTeos Therapeutics (ITOS)

Keep an eye on iTeos Therapeutics

Frequently Asked Questions

What is iTeos Therapeutics's (ITOS) price per share?

What is the 52-week high and low for iTeos Therapeutics (ITOS)?

Is iTeos Therapeutics (ITOS) a growth stock?

What is iTeos Therapeutics (ITOS) stock price performance year to date (YTD)?

Is iTeos Therapeutics (ITOS) a profitable company?

What is the market capitalization of iTeos Therapeutics (ITOS)?

News

Sign up for our newsletter

Take Your Investments to a Whole New Level